Overview

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

Status:
COMPLETED
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.
Phase:
PHASE4
Details
Lead Sponsor:
Istanbul Training and Research Hospital
Treatments:
Botulinum Toxins, Type A
Sodium Chloride